CA
AUPH icon

Clearstead Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Clearstead Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$612 Buy
+36
New +$575 ﹤0.01% 2861
2026
Q1 		– Sell
-2
Closed -$32 – 2299
2025
Q4 		$32 Sell
2
-385
-99% -$5.46K ﹤0.01% 2649
2025
Q3 		$4.28K Buy
387
+55
+17% +$601 ﹤0.01% 2215
2025
Q2 		$2.81K Buy
+332
New +$2.66K ﹤0.01% 2251

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Clearstead Advisors's AUPH Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Aurinia Pharmaceuticals (AUPH) in Q2 2026: 36 shares worth $612. The stake represents ﹤0.01% of the portfolio and ranks #2861 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in AUPH as recently as Q4 2025.

Clearstead Advisors first reported a position in AUPH in Q2 2025 and has held it in 4 quarters since. The position peaked at $4.28K in Q3 2025. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Clearstead Advisors held 36 shares of Aurinia Pharmaceuticals worth $612 as of Q2 2026.
  • Aurinia Pharmaceuticals was a new Clearstead Advisors position in Q2 2026.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2861 holding.
  • Clearstead Advisors first reported a position in Aurinia Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Clearstead Advisors's Aurinia Pharmaceuticals position peaked at $4.28K in Q3 2025.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.